GSK partners with Bluebird to commercialise gene therapies

03-05-2017

GSK partners with Bluebird to commercialise gene therapies

solidcolours / iStockphoto.com

GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform. 


GSK, Bluebird Bio, patent, licence agreement, HIV, genetic, rare disease, gene therapy, gene, genetics

LSIPR